Compare ARGX & DLTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARGX | DLTR |
|---|---|---|
| Founded | 2008 | 1986 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Department/Specialty Retail Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.9B | 20.9B |
| IPO Year | 2017 | 1996 |
| Metric | ARGX | DLTR |
|---|---|---|
| Price | $765.43 | $106.34 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 19 | 18 |
| Target Price | ★ $1,008.56 | $123.94 |
| AVG Volume (30 Days) | 302.5K | ★ 2.8M |
| Earning Date | 05-07-2026 | 03-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 144.33 |
| EPS | N/A | ★ 6.22 |
| Revenue | N/A | ★ $19,411,800,000.00 |
| Revenue This Year | $43.21 | $8.51 |
| Revenue Next Year | $21.79 | $6.00 |
| P/E Ratio | $33.69 | ★ $17.84 |
| Revenue Growth | N/A | ★ 10.43 |
| 52 Week Low | $510.06 | $68.93 |
| 52 Week High | $934.62 | $142.40 |
| Indicator | ARGX | DLTR |
|---|---|---|
| Relative Strength Index (RSI) | 60.56 | 40.39 |
| Support Level | $749.75 | $103.00 |
| Resistance Level | $779.00 | $116.14 |
| Average True Range (ATR) | 18.09 | 3.54 |
| MACD | 12.42 | 0.69 |
| Stochastic Oscillator | 99.42 | 41.87 |
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2024, Dollar Tree generated over $17 billion in sales, through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.